<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001547.v1.p1" parentStudy="phs001547.v1.p1" createDate="2018-02-14" modDate="2020-03-17">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Ingrid E. Christophersen, MD, PhD</td><td>Medical population genetics program, Broad Institute of MIT and Harvard and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA; Department of Medical Research, B&#230;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway</td></tr>
		<tr><td>Co-Investigator</td><td>Arnljot Tveit, MD, PhD</td><td>Department of Medical Research, B&#230;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>NHLBI TOPMed - NHGRI CCDG: The GENetics in Atrial Fibrillation (GENAF) Study</StudyNameEntrez>
	<StudyNameReportPage>NHLBI TOPMed - NHGRI CCDG: The GENetics in Atrial Fibrillation (GENAF) Study</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The Genetics in AF (GENAF) study enrolled individuals with early-onset lone AF before age 50 in Norway between 2009 and 2016. Early-onset was defined as diagnosis of AF before age 50. Lone AF was defined as AF in the absence of clinical or echocardiographic findings of cardiovascular disease, hypertension, metabolic or pulmonary disease. AF was documented in ECG. All participants underwent clinical examination, including ECG, echocardiography, and blood draw, from which DNA has been extracted. The study conforms to the principles of the Declaration of Helsinki and was approved by the Regional Ethics Committee (REK) in Norway (Protocol reference number: 2009/2224-5). All included patients gave written informed consent.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p><b>Inclusion Criteria</b> <ul> <li>Age &#8805; 18 years</li> <li>Competency to consent</li> <li>Signed written, informed consent</li> <li>Atrial fibrillation documented in ECG (Atrial fibrillation of at least 30 seconds duration in ECG- or Holter- recording) before age 50 years</li> </ul> </p> <p><b>Exclusion Criteria</b> <ul> <li>AF secondary to cardiac or pulmonary disorder, such as: <ul> <li>Hypertension</li> <li>Heart failure</li> <li>Coronary heart disease</li> <li>COPD</li> <li>Pulmonary embolism</li> <li>Congenital structural heart disease</li> </ul> </li> <li>AF secondary to other conditions, such as: <ul> <li>Hyperthyroidism</li> <li>Infectious conditions</li> <li>Alcohol- or drug abuse</li> </ul> </li> <li>Other conditions which make a genetic cause of the arrhythmia unlikely, based on the investigators judgement.</li> </ul> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="23264583"/>
		</Publication>
		<Publication>
			<Pubmed pmid="23040431"/>
		</Publication>
		<Publication>
			<Pubmed pmid="24667784"/>
		</Publication>
		<Publication>
			<Pubmed pmid="24074973"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Atrial Fibrillation"/>
		<Disease vocab_source="MESH" vocab_term="Atrial Flutter"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Ingrid E. Christophersen, MD, PhD</AttName>
			<Institution>Medical population genetics program, Broad Institute of MIT and Harvard and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA; Department of Medical Research, B&#230;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Arnljot Tveit, MD, PhD</AttName>
			<Institution>Department of Medical Research, B&#230;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="HMB-NPU" longName="Health/Medical/Biomedical (NPU)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHLBI</DacName>
      <DacFullName>National Heart, Lung, and Blood Institute DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone/>
      <DacUrl/>
    </DacInfo>
    <Policy Policy_ID="phs001547.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001547.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001547.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Health/Medical/Biomedical (NPU)</ConsentName>
        <ConsentAbbrev>HMB-NPU</ConsentAbbrev>
        <UseLimitation>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Use of the data is limited to not-for-profit organizations.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>
  <Documents>
    <Document phd="phd008024.1" type="protocol" createDate="2019-09-25" modDate="2020-03-17">
      <OrigName>TOPMed_WGS_Methods_Freeze8.docx</OrigName>
      <DisplayName>TOPMed Whole Genome Sequencing Methods: Freeze 8</DisplayName>
      <Description>TOPMed Whole Genome Sequencing Methods: Freeze 8</Description>
      <displayStatus>stage-2</displayStatus>
      <xmlStatus>develop</xmlStatus>
    </Document>
  </Documents>



</Study>

</Studies>

</GaPExchange>
